🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

21 recruiting trials

for Multiple Sclerosis, Secondary Progressive

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis NCT06138132Phase 11 site📍 Palo Alto Stanford University · Tests: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen Home Based Functional Balance Intervention for Multiple Sclerosis NCT07355387NA1 site📍 Chicago University of Illinois at Chicago · Tests: Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibul… Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis NCT06890923Phase 21 site📍 Boston Tiziana Life Sciences LTD · Tests: Foralumab TZLS-401 100 µg Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis NCT07477639Phase 1, Phase 28 sites📍 La Jolla📍 Kansas City📍 Rochester Tr1X, Inc. · Tests: TRX319, Bendamustine Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628Phase 323 sites📍 Palo Alto📍 Aurora📍 Evanston National Institute of Allergy and Infectious Diseases (NIAI… · Tests: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). NCT05961644Phase 2, Phase 31 site📍 Warsaw Institute of Psychiatry and Neurology, Warsaw · Tests: Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis NCT07426991n/a2 sites📍 Düsseldorf📍 Mönchengladbach Heinrich-Heine University, Duesseldorf · Tests: No Intervention: Observational Cohort A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) NCT07840326Phase 23 sites📍 Atlanta📍 Raleigh📍 Columbus Sundance Biosciences, Inc. · Tests: SUN-627, Placebo "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS NCT07222618n/a1 site📍 San Francisco University of California, San Francisco Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis NCT05177523n/a1 site📍 Basel University Hospital, Basel, Switzerland · Tests: MRI, Neurocognitive examination for healthy subjects, blood sampling Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland) NCT06526364n/a1 site📍 Basel University Hospital, Basel, Switzerland · Tests: All participants will be asked to provide data and samples for collection and analysis. The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis NCT06599307Phase 21 site📍 Giza Cairo University · Tests: Rituximab, Saline (NaCl 0,9 %) (placebo) A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis NCT07225504Phase 3296 sites📍 Birmingham📍 Phoenix📍 Phoenix Novartis Pharmaceuticals · Tests: Remibrutinib (blinded), Placebo, Remibrutinib (Open label) Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis NCT07587125Phase 11 site📍 Xi'an Xijing Hospital · Tests: S103 cells SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis NCT03783416Phase 11 site📍 London Queen Mary University of London · Tests: Ixazomib (NINLARO®) capsules / Matching placebo capsules Intermittent Hypoxia in Persons With Multiple Sclerosis NCT06276634NA1 site📍 Chicago Shirley Ryan AbilityLab · Tests: Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis NCT07299019Phase 361 sites📍 Phoenix📍 Scottsdale📍 Fullerton Zenas BioPharma (USA), LLC · Tests: Orelabrutinib, Placebo Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS NCT06390930NA1 site📍 Chicago Shirley Ryan AbilityLab · Tests: Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders NCT06680037Phase 18 sites📍 La Jolla📍 Ann Arbor📍 Omaha TG Therapeutics, Inc. · Tests: Azercabtagene zapreleucel (azer-cel) MS-ResearchBiomarkerS NCT05204459n/a1 site📍 Los Angeles Cedars-Sinai Medical Center
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy